Literature DB >> 29089722

Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.

Nicholas Leon, Richard LaCoursiere, Deirdre Yarosh, Roshni S Patel.   

Abstract

Lixisenatide (Adlyxin), a once-daily incretin mimetic injection for type-2 diabetes.

Entities:  

Year:  2017        PMID： 29089722      PMCID： PMC5642155     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  28 in total

1.  Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.

Authors:  T Seck; M Nauck; D Sheng; S Sunga; M J Davies; P P Stein; K D Kaufman; J M Amatruda
Journal:  Int J Clin Pract       Date:  2010-04       Impact factor: 2.503

2.  Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.

Authors:  Graydon S Meneilly; Christine Roy-Duval; Hasan Alawi; George Dailey; Diego Bellido; Carlos Trescoli; Helard Manrique Hurtado; Hailing Guo; Valerie Pilorget; Riccardo Perfetti; Hamish Simpson
Journal:  Diabetes Care       Date:  2017-02-10       Impact factor: 19.112

3.  Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

Authors:  G B Bolli; M Munteanu; S Dotsenko; E Niemoeller; G Boka; Y Wu; M Hanefeld
Journal:  Diabet Med       Date:  2013-10-24       Impact factor: 4.359

4.  Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

Authors:  M Pinget; R Goldenberg; E Niemoeller; I Muehlen-Bartmer; H Guo; R Aronson
Journal:  Diabetes Obes Metab       Date:  2013-05-26       Impact factor: 6.577

5.  Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.

Authors:  G Bolli; F Dotta; E Rochotte; S E Cohen
Journal:  Diabetes Obes Metab       Date:  2007-11-22       Impact factor: 6.577

Review 6.  A Comparison of New Pharmacological Agents for the Treatment of Obesity.

Authors:  Wesley Nuffer; Jennifer M Trujillo; Jade Megyeri
Journal:  Ann Pharmacother       Date:  2016-02-17       Impact factor: 3.154

7.  Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).

Authors:  Matthew C Riddle; Ronnie Aronson; Philip Home; Michel Marre; Elisabeth Niemoeller; Patrick Miossec; Lin Ping; Jenny Ye; Julio Rosenstock
Journal:  Diabetes Care       Date:  2013-04-29       Impact factor: 19.112

8.  Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Authors:  Y Seino; K W Min; E Niemoeller; A Takami
Journal:  Diabetes Obes Metab       Date:  2012-05-30       Impact factor: 6.577

9.  Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Authors:  Michael Nauck; Anders Frid; Kjeld Hermansen; Nalini S Shah; Tsvetalina Tankova; Ismail H Mitha; Milan Zdravkovic; Maria Düring; David R Matthews
Journal:  Diabetes Care       Date:  2008-10-17       Impact factor: 17.152

10.  Diabetes and pregnancy: an endocrine society clinical practice guideline.

Authors:  Ian Blumer; Eran Hadar; David R Hadden; Lois Jovanovič; Jorge H Mestman; M Hassan Murad; Yariv Yogev
Journal:  J Clin Endocrinol Metab       Date:  2013-11       Impact factor: 5.958
View more
  6 in total

Review 1.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

2.  Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL).

Authors:  Hideaki Kaneto; Mike Baxter; Yoko Takahashi; Yasuo Terauchi
Journal:  Adv Ther       Date:  2022-10-07       Impact factor: 4.070

Review 3.  GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Authors:  Andrei C Sposito; Otávio Berwanger; Luiz Sérgio F de Carvalho; José Francisco Kerr Saraiva
Journal:  Cardiovasc Diabetol       Date:  2018-12-13       Impact factor: 9.951

4.  Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites.

Authors:  Maorong Wang; Ping Yao; Minpeng Gao; Jian Jin; Yerong Yu
Journal:  RSC Adv       Date:  2020-02-24       Impact factor: 4.036

5.  The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.

Authors:  Yasuo Terauchi; Makiko Usami; Tomoyuki Inoue
Journal:  Adv Ther       Date:  2022-04-21       Impact factor: 4.070

Review 6.  Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.

Authors:  Elpiniki Rentzeperi; Stavroula Pegiou; Theocharis Koufakis; Maria Grammatiki; Kalliopi Kotsa
Journal:  J Pers Med       Date:  2022-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.